How to access Zynteglo in the UAE: the named-patient access pathway, 2026
By the Reserve Meds Clinical and Regulatory Team. Last reviewed 2026-05-31.
Zynteglo (betibeglogene autotemcel) is FDA-approved for transfusion-dependent beta-thalassemia in patients who require regular red blood cell transfusions. In the UAE, it is available through the Emirates Drug Establishment (EDE) named-patient import framework. Reserve Meds coordinates the sourcing, documentation, and cold-chain logistics for UAE-based families and their physicians.
Request access to Zynteglo in the UAE
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
The clinical situation
Zynteglo (betibeglogene autotemcel) is an autologous ex vivo lentiviral gene therapy developed by Bluebird Bio. The FDA approved it in August 2022 for transfusion-dependent beta-thalassemia (TDT) in adult and pediatric patients who require regular red blood cell transfusions. A lentiviral vector inserts a functional beta-A-T87Q-globin transgene into the patient's own CD34+ haematopoietic stem and progenitor cells. After myeloablative conditioning and reinfusion, the edited cells restore haemoglobin synthesis. In the pivotal Northstar, Northstar-2, Northstar-3, and HGB studies, the majority of treated patients achieved transfusion independence or a substantial reduction in transfusion requirement.
The UAE's large South Asian and Arab expatriate population carries elevated beta-thalassemia carrier rates from origin countries where the condition is common. TDT families in the UAE have typically managed the condition through chronic transfusion and chelation for years. Zynteglo represents a one-time intervention that addresses the genetic deficit rather than managing it on a rolling basis.
Is Zynteglo available in the UAE?
As of December 2025, under Federal Decree-Law No. 38 of 2024, the Emirates Drug Establishment (EDE) assumed pharmaceutical regulatory functions from MOHAP, including named-patient import permits. Local registration status for Zynteglo in the UAE may shift over time; the drug may be registered for some indications but not others, or the registered presentation may not match what the prescribing physician needs. The EDE named-patient framework exists precisely to bridge those gaps.
When the local registered supply does not match the prescription, a UAE-licensed physician can apply through the EDE portal at ede.gov.ae for a named-patient import permit. This permits import of a drug approved by a recognised reference authority (the US FDA qualifies) for a specific named patient when the treating consultant at a licensed UAE facility documents the clinical justification and no clinically suitable locally registered equivalent exists for this patient's specific case.
How the pathway works
A UAE-licensed haematologist at an appropriate facility initiates the EDE named-patient application. The application documents the TDT diagnosis and severity, the prior transfusion history, the physician's rationale for Zynteglo, and confirmation that the locally registered supply does not meet this patient's clinical need. Full product details, dispensing facility information, and a chain-of-custody plan are included. Reserve Meds provides a documentation coordination kit to support the physician's filing. EDE routine review typically runs 5 to 15 business days for a complete application. Complex gene therapy cases with first-import scrutiny may extend to 4 to 6 weeks. The four-to-six-month Bluebird Bio manufacturing period after cell collection means the EDE review is one of several parallel workstreams rather than the binding constraint.
What your physician needs to know
Your treating haematologist initiates the EDE named-patient application. Reserve Meds provides a coordination kit covering the documentation structure, dispensing facility requirements, and chain-of-custody standards the EDE expects for gene therapy imports. The kit goes to your physician at intake. The document checklist is a concierge deliverable, not a self-service guide published here.
For autologous gene therapy in the UAE, the receiving centre must hold the qualified-treatment-centre infrastructure: apheresis, myeloablative conditioning capability, infusion suite, and post-infusion monitoring. In Abu Dhabi, Cleveland Clinic Abu Dhabi on Al Maryah Island and Sheikh Khalifa Medical City are the primary tertiary referral centres. In Dubai, American Hospital Dubai (Mayo Clinic Care Network member) and King's College Hospital London Dubai are established specialty haematology centres. Your haematologist identifies the appropriate facility based on your case.
Indicative cost and timing
Zynteglo's list price in the US is approximately USD 2.8 million for the one-time infusion product. The UAE dirham is pegged to the US dollar at approximately 3.67 AED to 1 USD, so the indicative drug cost is approximately AED 10.3 million. Total cost of care, including workup, mobilisation, apheresis, the manufacturing wait, conditioning, inpatient admission, and first-year monitoring, is substantially higher. These are illustrative figures. Reserve Meds issues a full transparent quote at intake with every cost line itemised separately.
EDE routine review typically runs 5 to 15 business days for a complete application. The full treatment arc from first engagement to completed infusion is approximately one year, driven primarily by the manufacturing period. For longer treatment coordination, Reserve Meds manages ongoing logistics so families are never managing the supply chain themselves.
UAE insurers including Daman, Thiqa (government-funded for UAE nationals), GIG Gulf, Sukoon, ADNIC, and Orient assess named-patient imports case by case. Reserve Meds provides the documentation set that supports the prior-authorisation review. We do not guarantee coverage from any insurer. US manufacturer copay programmes do not extend internationally; cross-border patients rely on local payer coverage or pay cash.
Cost and timing figures are indicative. They reflect current market data and are not a guarantee. Reserve Meds provides a detailed quote at intake.
Reserve Meds's role
- Sourcing. US-side procurement through a DSCSA-compliant specialty channel with full serial traceability from Bluebird Bio through to the UAE receiving pharmacy.
- Documentation. Coordination kit for the treating physician's EDE application; chain-of-custody attestation for the import file.
- Logistics. Validated cold-chain shipment with continuous temperature logging. The cold chain is managed from the US manufacturer through to the dispensing pharmacy's validated storage. Customs clearance is scheduled to avoid prolonged tarmac exposure in Gulf heat.
- Named case manager. A single coordinator assigned from intake through post-infusion follow-up, keeping the clinical team, the family, and the logistics track aligned.
Reserve Meds is not your treating physician. We do not practise medicine. We do not manufacture Zynteglo. We do not own or operate Cleveland Clinic Abu Dhabi, Sheikh Khalifa Medical City, American Hospital Dubai, King's College Hospital London Dubai, or any other treatment centre. Clinical decisions remain with your treating haematologist. See reservemeds.com/trust for our full operating scope and limitations.
Frequently asked questions
Is Zynteglo available in the UAE?
Zynteglo (betibeglogene autotemcel) is FDA-approved for transfusion-dependent beta-thalassemia. In the UAE, it is available through the EDE named-patient import framework when the local registered supply does not match the physician's prescription. Reserve Meds coordinates the documentation and logistics.
Is importing Zynteglo to the UAE legal?
Yes, when coordinated through the EDE named-patient import mechanism with a UAE-licensed physician's authorisation and compliant chain-of-custody documentation. Reserve Meds operates within this legal framework. See reservemeds.com/trust.
Which UAE hospitals can administer Zynteglo?
Autologous gene therapy requires the full apheresis, conditioning, infusion, and monitoring infrastructure of a qualified treatment centre. Cleveland Clinic Abu Dhabi and Sheikh Khalifa Medical City are the primary Abu Dhabi options. American Hospital Dubai and King's College Hospital London Dubai serve Dubai-based families. Your haematologist confirms the appropriate receiving facility.
Will UAE insurance cover Zynteglo?
UAE insurers assess named-patient imports case by case. Reserve Meds provides the documentation that supports the prior-authorisation submission. We do not guarantee coverage.
How long does the pathway take?
EDE routine review typically runs 5 to 15 business days for a complete application. The manufacturing period after cell collection adds four to six months. Total arc from first engagement to infusion is approximately one year.
Next step: request access
If your UAE physician has recommended Zynteglo and you are weighing the named-patient pathway, the next step is a short intake. We confirm eligibility and pathway fit within 24 to 48 hours and send a documentation kit to your haematologist.
Reserved for you.
Composite case examples; no individual patient is depicted. This content is for general information and does not constitute medical advice. Reserve Meds is a US-based concierge coordinator; we are not the prescriber and not the dispensing pharmacy. Clinical decisions remain with your treating haematologist.
Clinical and regulatory review: Reserve Meds Clinical and Regulatory Team. Last medically reviewed: 2026-05-31.